PD-L1 Expression Is an Independent Marker for Lymph Node Metastasis in Middle Eastern Endometrial Cancer
Authors:
- Abdul K. SirajASAbdul K. Siraj
- Sandeep Kumar ParvathareddySPSandeep Kumar Parvathareddy
- Padmanaban AnnaiyappanaiduPAPadmanaban Annaiyappanaidu
- Nabil SirajNSNabil Siraj
- Maha Al-RasheedMAMaha Al-Rasheed
- Ismail A. Al-BadawiIAIsmail A. Al-Badawi
- Fouad Al-DayelFAFouad Al-Dayel
- Khawla S. Al-KurayaKAKhawla S. Al-Kuraya
Open Access
- 25 February 2021
- journal article
- research article
- Published by MDPI AG in Diagnostics
- Vol. 11 (3) , 394
Abstract
Programmed death ligand 1 (PD-L1) expression in endometrial cancer (EC) tumor cells have been reported in several studies with inconsistent results. Furthermore, there is scarcity of data on the prevalence and prognostic significance of PD-L1 expression in EC from Middle Eastern ethnicity. We aimed to assess PD-L1 expression in a large cohort of Middle Eastern EC and to correlate this with clinico-pathological factors, as well as mismatch repair (MMR) protein status and patients’ outcome. PD-L1 expression was investigated using immunohistochemistry on tissue microarray in an unselected cohort of 440 EC. Kaplan–Meier and logistic regression analysis were used to compare the outcome and prognostic factors. PD-L1 expression in tumor tissue was detected in 18.9% (83/440) EC cases with no impact on survival. When stratified for MMR protein status, PD-L1 expression was similar for both MMR deficient and MMR proficient ECs. However, the expression of PD-L1 in tumor cells was significantly associated with type II (non-endometrioid) histology (p = 0.0005) and lymph node metastasis (p = 0.0172). Multivariate analysis showed PD-L1 expression to be an independent risk factor for lymph node metastasis (odds ratio: 2.94; 95% CI: 1.26–6.84; p = 0.0123). In conclusion, PD-L1 was strongly associated with non-endometrioid EC and was an independent prognostic marker of lymph node metastasis.Keywords
This publication has 41 references indexed in Scilit:
- Atezolizumab, an Anti–Programmed Death-Ligand 1 Antibody, in Metastatic Renal Cell Carcinoma: Long-Term Safety, Clinical Activity, and Immune Correlates From a Phase Ia StudyJournal of Clinical Oncology, 2016
- PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: Mechanisms, response biomarkers, and combinationsScience Translational Medicine, 2016
- ESMO-ESGO-ESTRO Consensus Conference on Endometrial CancerInternational Journal of Gynecological Cancer, 2016
- Regulation of PD-L1: a novel role of pro-survival signalling in cancerAnnals of Oncology, 2015
- Pembrolizumab for the treatment of PD-L1 positive advanced or metastatic non-small cell lung cancerExpert Review of Anticancer Therapy, 2015
- Association of Polymerase e–Mutated and Microsatellite-Instable Endometrial Cancers With Neoantigen Load, Number of Tumor-Infiltrating Lymphocytes, and Expression of PD-1 and PD-L1JAMA Oncology, 2015
- Prevalence of Lynch syndrome in a Middle Eastern population with colorectal cancerCancer, 2015
- The blockade of immune checkpoints in cancer immunotherapyNature Reviews Cancer, 2012
- Genome‐wide expression analysis of Middle Eastern papillary thyroid cancer reveals c‐MET as a novel target for cancer therapyThe Journal of Pathology, 2007
- Prevalence of Fragile Histidine Triad Expression in Tumors from Saudi Arabia: A Tissue Microarray AnalysisCancer Epidemiology, Biomarkers & Prevention, 2006